Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with dose-inte...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rangwala, Reshma, Leone, Robert, Chang, Yunyoung C, Fecher, Leslie A, Schuchter, Lynn M, Kramer, Amy, Tan, Kay-See, Heitjan, Daniel F, Rodgers, Glenda, Gallagher, Maryann, Piao, Shengfu, Troxel, Andrea B, Evans, Tracey L, DeMichele, Angela M, Nathanson, Katherine L, O’Dwyer, Peter J, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, Amaravadi, Ravi K
Formato: Artigo
Lenguaje:Inglês
Publicado: Landes Bioscience 2014
Materias:
Clinical Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4203514/
https://ncbi.nlm.nih.gov/pubmed/24991839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/auto.29118
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares